Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Executive Profile: Pfizer's Geno Germano On Impatience, Innovation And The Influence Of Culture

This article was originally published in Scrip

Executive Summary

Geno Germano is group president of Pfizer's Global Innovative Pharma Business, the unit focused on development, registration and commercialization of novel medicines. He is co-chair of the portfolio strategy and investment committee, which aims to maximize the return on R&D investment across the Pfizer portfolio. Germano also manages Pfizer's global health and value function, which works to demonstrate the value of innovation and supports access to Pfizer's medicines. In the latest edition of Scrip's executive profile series, he tells Sukaina Virji of his childhood propensity for hard work, how youthful impatience led him to a successful career in the pharmaceutical industry, and the influence of culture on effectiveness.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts